drug_type
RELEVANT_DRUG
intervention_type
Biological (adoptive cellular immunotherapy)
drug_description
Patient-derived T cells primed and expanded ex vivo against individualized tumor neoantigens using autologous antigen-presenting cells, then infused intravenously to mediate TCR-dependent cytotoxicity against neoantigen-expressing cancer cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Autologous
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are primed and expanded ex vivo against patient-specific tumor neoantigens and, after infusion, use their endogenous TCRs to recognize neoantigen peptides presented by MHC on tumor cells, inducing cytotoxic killing via perforin/granzyme and antitumor cytokine release.
drug_name
Autologous tumor neoantigen‑specific T cells (NeoT)
nct_id_drug_ref
NCT06431529